452 related articles for article (PubMed ID: 29967022)
1. Pharmacodynamic Target Attainment for Cefepime, Meropenem, and Piperacillin-Tazobactam Using a Pharmacokinetic/Pharmacodynamic-Based Dosing Calculator in Critically Ill Patients.
Heil EL; Nicolau DP; Farkas A; Roberts JA; Thom KA
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29967022
[TBL] [Abstract][Full Text] [Related]
2. Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Landmesser KB; Clark JA; Burgess DS
J Clin Pharmacol; 2022 Apr; 62(4):479-485. PubMed ID: 34614542
[TBL] [Abstract][Full Text] [Related]
3. OTAC: Optimization of Antibiotic Therapy in Critically ill Patients. Using beta-lactam antibiotics by continuous infusion.
Esteve-Pitarch E; Padullés-Zamora A; Maisterra-Santos K; Colom-Codina H; Cobo-Sacristán S
Farm Hosp; 2019 Sep; 43(5):151-157. PubMed ID: 31469627
[TBL] [Abstract][Full Text] [Related]
4. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
[TBL] [Abstract][Full Text] [Related]
5. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Sun HK; Kuti JL; Nicolau DP
Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
[TBL] [Abstract][Full Text] [Related]
7. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
Carlier M; Carrette S; Roberts JA; Stove V; Verstraete A; Hoste E; Depuydt P; Decruyenaere J; Lipman J; Wallis SC; De Waele JJ
Crit Care; 2013 May; 17(3):R84. PubMed ID: 23642005
[TBL] [Abstract][Full Text] [Related]
8. Beta-lactam antibiotic concentrations in critically ill patients with standard and adjusted dosages: A prospective observational study.
Areskog Lejbman I; Torisson G; Resman F; Sjövall F
Acta Anaesthesiol Scand; 2024 Apr; 68(4):530-537. PubMed ID: 38407447
[TBL] [Abstract][Full Text] [Related]
9. A pilot study on pharmacokinetic/pharmacodynamic target attainment in critically ill patients receiving piperacillin/tazobactam.
Martínková J; Malbrain ML; Havel E; Šafránek P; Bezouška J; Kaška M
Anaesthesiol Intensive Ther; 2016; 48(1):23-8. PubMed ID: 26588478
[TBL] [Abstract][Full Text] [Related]
10. Optimal antipseudomonal ꞵ-lactam drug dosing recommendations in critically-ill Asian patients receiving CRRT.
Jang SM; Lewis SJ; Rhie SJ
J Crit Care; 2022 Dec; 72():154172. PubMed ID: 36270240
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of piperacillin and tazobactam in critically Ill patients treated with continuous kidney replacement therapy: A mini-review and population pharmacokinetic analysis.
Selig DJ; DeLuca JP; Chung KK; Pruskowski KA; Livezey JR; Nadeau RJ; Por ED; Akers KS
J Clin Pharm Ther; 2022 Aug; 47(8):1091-1102. PubMed ID: 35352374
[TBL] [Abstract][Full Text] [Related]
12. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
[TBL] [Abstract][Full Text] [Related]
13. Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.
Taccone FS; Laterre PF; Dugernier T; Spapen H; Delattre I; Wittebole X; De Backer D; Layeux B; Wallemacq P; Vincent JL; Jacobs F
Crit Care; 2010; 14(4):R126. PubMed ID: 20594297
[TBL] [Abstract][Full Text] [Related]
14. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.
Abdul-Aziz MH; Lipman J; Akova M; Bassetti M; De Waele JJ; Dimopoulos G; Dulhunty J; Kaukonen KM; Koulenti D; Martin C; Montravers P; Rello J; Rhodes A; Starr T; Wallis SC; Roberts JA;
J Antimicrob Chemother; 2016 Jan; 71(1):196-207. PubMed ID: 26433783
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of pharmacokinetic/pharmacodynamic and clinical outcomes with 6-hourly empiric piperacillin-tazobactam dosing in hematological malignancy patients with febrile neutropenia.
Weber N; Jackson K; McWhinney B; Ungerer J; Kennedy G; Lipman J; Roberts JA
J Infect Chemother; 2019 Jul; 25(7):503-508. PubMed ID: 30879981
[TBL] [Abstract][Full Text] [Related]
16. Is high-dose β-lactam therapy associated with excessive drug toxicity in critically ill patients?
McDonald C; Cotta MO; Little PJ; McWhinney B; Ungerer JP; Lipman J; Roberts JA
Minerva Anestesiol; 2016 Sep; 82(9):957-65. PubMed ID: 27054905
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring of meropenem and piperacillin-tazobactam in the Singapore critically ill population - A prospective, multi-center, observational study (BLAST 1).
Chua NG; Loo L; Hee DKH; Lim TP; Ng TM; Hoo GSR; Soong JL; Ong JCL; Tang SSL; Zhou YP; Lee W; Lee LS; Cove M; Ling LM; Kwa AL
J Crit Care; 2022 Apr; 68():107-113. PubMed ID: 34999376
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
Asín-Prieto E; Rodríguez-Gascón A; Trocóniz IF; Soraluce A; Maynar J; Sánchez-Izquierdo JÁ; Isla A
J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy.
Lewis SJ; Mueller BA
BMC Nephrol; 2024 Feb; 25(1):73. PubMed ID: 38413858
[TBL] [Abstract][Full Text] [Related]
20. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]